Resources

The positive impact of adjuvants on vaccination can be functional and practical. A handful of adjuvants are currently licensed for human vaccination, and a number of new adjuvants have reached advanced development stages. However, access to these and other adjuvants is limited. Presented at the 2012 Conference on Modern Vaccines Adjuvants and Delivery Systems, this poster outlines PATH’s work to expand access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.

This fact sheet describes the positive impact that adjuvants can have on vaccine efficacy and, potentially, immunization program costs. It also describes PATH’s work to expand global access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.

This fact sheet describes PATH's strategic approach to improving sanitation in low-resource settings.

PATH’s Safe Water Project is implementing innovative methods to enable commercial enterprises to produce, distribute, sell, and maintain effective household water treatment and safe storage products for low-income populations in multiple developing countries around the world. This fact sheet summarizes PATH's work in partnership with Hydrologic Social Enterprise and VisionFund to explore the viability of distributing household water treatment devices through retail and direct sales models.

Since 2003, PATH has conducted a wide range of activities to inform and advance the development of novel microbicide-delivery methods that are safe, acceptable, affordable, and appropriate for use in low-resource settings. This fact sheet describes how PATH identified a paper, user-filled applicator as an important, practical option that could help reduce cost per dose, thereby improving access to microbicide products in impoverished regions most affected by HIV.